Predictive Oncology raises $343.5M to fund Aethir investment

Predictive Oncology (POAI), a Nasdaq-listed company that previously announced plans to focus its investments on Aethir (ATH), has raised a total of $343.5 million through a private investment in public equity (PIPE) offering. The funding includes $50.8 million in cash and $292.7 million worth of ATH. The company plans to use the acquired ATH for its Digital Asset Treasury (DAT) strategy and the cash to purchase additional ATH on the open market.